Clinical Trial Detail

NCT ID NCT02339558
Title Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

nasopharynx carcinoma

Therapies

Nivolumab

Age Groups: adult

No variant requirements are available.